Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
April 27, 2022 07:30 ET
|
Repligen Corporation
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base...
Repligen to Report First Quarter 2022 Financial Results
April 13, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27,...
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
March 18, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022 07:30 ET
|
Repligen Corporation
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic...
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
February 15, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
February 11, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
February 03, 2022 09:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday,...
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
December 30, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Corporation to Present at Upcoming Investor Conferences
November 12, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Releases Inaugural Sustainability Report
November 05, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website. Repligen’s 2020...